Skip to main content

Table 1 Comparison of clinical and biological characteristics between acute myeloid leukemia (AML) patients, with or without GATA-1 and GATA-2 expression

From: Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF)

 

Gata-1 positive

Gata-1 negative

P

Gata-2 positive

Gata-2 negative

P

Gender of patients (male/female)

25/10

12/18

0.011

25/15

12/13

0.251

Age/years (median)

57.3

42.2

0.011

52.7

44.7

0.187

Status Performance/ECOG

6/11/12/6/0

11/7/8/3/1

0.308

10/13/11/5/1

7/5/9/4/0

0.728

WBC count, x109/L(median)

34.98

34.34

0.965

30.6

41.1

0.473

Hemoglobin, g/dL (median)

9.3

9.8

0.303

9.8

9.3

0.168

platelet count, x109/L (median)

103.4

75.4

0.219

102.2

73.6

0.217

Percentage of Blasts in PB (median)

36.7

49

0.153

42.8

41.6

0.885

M2 vs. non-M2 FAB

5/29

6/24

0.575

6/33

5/20

0.633

M3 vs.non-M3 FAB

4/30

5/24

0.536

6/33

3/21

0.751

WHO Type

8/9/2/14

6/7/1/15

0.885

9/10/2/17

5/6/1/2

0.980

Primary/Secondary LMA

25/10

26/4

0.136

31/9

20/5

0.811

Cytogenetic (MRC)

8/16/7

7/15/5

0.924

10/20/5

5/11/7

0.329

Cr 7 Alterations (yes/no)

3/28

4/24

0.585

1/35

6/17

0.007

Cr 5 Alterations (yes/no)

2/29

5/23

0.176

2/34

5/18

0.061

Cr 11 Alterations (yes/no)

5/26

6/22

0.602

3/33

8/15

0.011

CD34 Blasts (yes/no)

19/16

14/15

0.820

20/19

13/12

0.955

CD117 Blasts (yes/no)

25/10

16/13

0.177

25/14

16/9

0.993

CD15 Blasts (yes/no)

16/15

15/13

0.880

17/19

14/9

0.306

CD11B Blasts (yes/no)

10/21

8/18

0.945

12/24

6/15

0.709

CD11C Blasts (yes/no)

8/1

7/3

0.313

5/7

10/2

0.539

CD 133 Blasts (yes/no)

11/16

9/11

0.770

12/17

8/10

0.836

CD 123 Blasts (yes/no)

6/14

6/9

0.537

4/18

8/5

0.009

HLA DR + Blasts (yes/no)

21/7

13/14

0.040

23/11

11/10

0.258

CD56 Blast (yes/no)

5/30

6/24

0.540

6/34

5/20

0.601

T-cell markers Blast (yes/no)

5/13

4/18

0.470

5/15

4/16

0.705

Erythroblasts BM

1/8/12

1/12/9

0.359

1/10/11

1/10/10

0.335

Gata-1 Expression (yes/no)

   

25/15

10/15

0.077

Gata-2 Expression (yes/no)

25/15

10/15

0.077

   

EKLF Expression (yes/no)

24/11

11/19

0/010

27/13

8/17

0.005

cMPL Expression (yes/no)

26/9

20/10

0.501

31/9

15/10

0.131

Gata-1 (Median Expression)*

   

6.37

0.14

0.090

Gata-2 (Median Expression)

253.1

1545.85

0.182

   

EKLF (Median Expression)

27.4

1.6

0.019

20.4

7.6

0.017

cMPL (Median Expression)*

9.2

11.5

0.780

11.97

7.50

0.181

Mutated NPM1 (yes/no)

4/20

5/15

0.495

6/22

3/13

0.832

Mutated FLT3 (yes/no)

2/22

7/13

0.029

6/22

3/13

0.832

  1. PS, Performance Status. WBC, white blood cell. FAB indicates French American British classification [19] and WHO indicates World Health Organization classification [20]. MRC, cytogenetic classification of Medical Research Cancer [21]. GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), Erythroid Krüppel-like Factor (EKLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL). * All expression ratios are given as 100x target gene/GUS.
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us